Patents Assigned to Vertex Pharmaceuticals, Incorporated
-
Publication number: 20240173432Abstract: Compositions and methods for treating Myotonic Dystrophy Type 1 (DM1) are encompassed.Type: ApplicationFiled: August 25, 2023Publication date: May 30, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Guoxiang Ruan, Jianming Liu, Tudor Fulga, Mehmet Fatih Bolukbasi, Eric Gunnar Anderson, Lingjun Rao, Norzehan Abdul-Manan, Matthias Heidenreich, Gregoriy Aleksandrovich Dokshin, Jesper Gromada
-
Patent number: 11992506Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.Type: GrantFiled: November 1, 2022Date of Patent: May 28, 2024Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
-
Publication number: 20240156738Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.Type: ApplicationFiled: July 20, 2023Publication date: May 16, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
-
Patent number: 11980633Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.Type: GrantFiled: July 29, 2021Date of Patent: May 14, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Diane Boucher, Shawn M. Hillier, Wanjung Tsai, Brian Hare, William Markland, David A. Newsome, Marina S. Penney
-
Publication number: 20240148642Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.Type: ApplicationFiled: January 18, 2024Publication date: May 9, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: CHRISTOPHER THANOS, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Publication number: 20240117319Abstract: The present application discloses cell clusters resembling the function and characteristics of endogenous pancreatic islets, and methods for making and using such cell clusters.Type: ApplicationFiled: December 21, 2023Publication date: April 11, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Yeh-Chuin POH, George HARB, Felicia J. PAGLIUCA
-
Publication number: 20240117318Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.Type: ApplicationFiled: December 21, 2023Publication date: April 11, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: George Harb, Chunhi Xie
-
Patent number: 11951206Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.Type: GrantFiled: September 29, 2018Date of Patent: April 9, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Patent number: 11951212Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.Type: GrantFiled: March 17, 2021Date of Patent: April 9, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
-
Patent number: 11945795Abstract: Disclosed herein are compositions and methods useful for manufacturing SC-? cell, and isolated populations of SC-? cells for use in various applications, such as cell therapy.Type: GrantFiled: May 1, 2020Date of Patent: April 2, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Austin Thiel, Jihad Yasin, Evrett Thompson, Felicia J. Pagliuca
-
Patent number: 11919887Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.Type: GrantFiled: November 8, 2022Date of Patent: March 5, 2024Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
-
Publication number: 20240033216Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.Type: ApplicationFiled: September 21, 2023Publication date: February 1, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Patent number: 11884672Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: GrantFiled: May 13, 2020Date of Patent: January 30, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
-
Patent number: 11873300Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.Type: GrantFiled: August 13, 2020Date of Patent: January 16, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
-
Patent number: 11866446Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).Type: GrantFiled: August 26, 2021Date of Patent: January 9, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jun Myun Ahn, Samantha Angle, Michael Aaron Brodney, Jingrong Cao, John E. Cochran, Jon H. Come, Leslie A. Dakin, Elena Dolgikh, Brad D. Maxwell, Suganthini S. Nanthakumar, Hardwin O'Dowd, Jessica Howard Olsen, Timothy J. Senter, Akira Joseph Shimizu, Steven David Stone, Haoxuan Wang
-
Patent number: 11866450Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.Type: GrantFiled: May 18, 2021Date of Patent: January 9, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
-
Publication number: 20230414648Abstract: Compositions and methods for treating myotonic dystrophy type 1 (DM1) with SluCas9 and SaCas9 are encompassed.Type: ApplicationFiled: November 5, 2021Publication date: December 28, 2023Applicant: Vertex Pharmaceuticals IncorporatedInventors: John Patrick Leonard, Zachary Michael Detwiler, Peter Thomas Hallock, Eric Gunnar Anderson
-
Publication number: 20230390400Abstract: A method of manufacturing a macroencapsulation device includes aligning one or more membranes of the device with a frame of the device, such that a portion of the one or more membranes overlap a portion of the frame. The method also includes deforming the one or more membranes and thermoplastically deforming the frame to form mechanically interlocked regions of the membrane and the frame.Type: ApplicationFiled: June 6, 2023Publication date: December 7, 2023Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Megan Billings, Matthew Watson
-
Patent number: 11834441Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.Type: GrantFiled: December 4, 2020Date of Patent: December 5, 2023Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Steven John Durrant, Nadia Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
-
Patent number: 11827627Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.Type: GrantFiled: June 3, 2022Date of Patent: November 28, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
